Ki-Hyun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ki-Hyun Kim has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Hyung-Hoon Oh
Department of Internal Medicine Chonnam National University Medical School Gwangju Republic of Korea
3 shared publications - Young-Eun Joo
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
3 shared publications - Chae June Lim
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
2 shared publications - Chan-Muk Im
Department of Internal Medicine, Chonnam National University Medical School, Jeonnam-Gwangju, Korea
2 shared publications - Chang-Hwan Park
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
2 shared publications - Dong Wook Lee
Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
2 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 14 (1) , 115-119
Long-term Survival after Surgery in a Patient with Small Bowel Metastasis of Hepatocellular Carcinoma: A Case Report and Literature Review
Je Seong Kim, Won Jae Lee, Chae June Lim, Young Eun Seo, Chan Muk Im, Hyung Hoon Oh, Ki-Hyun Kim, Young Eun Joo. Journal of Digestive Cancer Research 2026;14:115-9. https://doi.org/10.52927/jdcr.2026.14.1.115
- 20 April 2026
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 14 (1) , 115-119
Open AccessLong-term Survival after Surgery in a Patient with Small Bowel Metastasis of Hepatocellular Carcinoma: A Case Report and Literature Review
Je Seong Kim, Won Jae Lee, Chae June Lim, Young Eun Seo, Chan Muk Im, Hyung Hoon Oh, Ki-Hyun Kim, Young Eun Joo. Journal of Digestive Cancer Research 2026;14:115-9. https://doi.org/10.52927/jdcr.2026.14.1.115
- Open Access
- 20 December 2025
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 13 (3) , 302-308
Serial Pancreatic Juice Aspiration Cytology: Advancing Insights into Early Pancreatic Cancer Diagnosis
Ki-Hyun Kim. Journal of Digestive Cancer Research 2025;13:302-8. https://doi.org/10.52927/jdcr.2025.13.3.302
- 20 December 2025
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 13 (3) , 302-308
Open AccessSerial Pancreatic Juice Aspiration Cytology: Advancing Insights into Early Pancreatic Cancer Diagnosis
Ki-Hyun Kim. Journal of Digestive Cancer Research 2025;13:302-8. https://doi.org/10.52927/jdcr.2025.13.3.302
- Open Access
- 10 December 2025
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 25 (4) , 363-370
Endoscopic Diagnosis and Clinical Course of Isolated Upper Gastrointestinal Amyloidosis: A Retrospective Observational Study
Objectives: Early diagnosis of upper gastrointestinal (UGI) amyloidosis and the establishment of appropriate treatment and follow-up strategies remains challenging. This study aimed to elucidate the endoscopic characteristics and clinical courses of patients with isolated UGI amyloidosis. Methods: We retrospectively reviewed 11 patients diagnosed with isolated UGI amyloidosis at Chonnam National University Hospital and Chonnam National University Hwasun Hospital. None of the patients exhibited systemic involvement or multiple myeloma. Clinical data, including endoscopic features, presenting symptoms, and outcomes such as disease progression and mortality, were analyzed. Results: The cohort included seven males (63.6%) and four females (36.4%), with a median age of 72 (37–82) years. Isolated gastric amyloidosis was identified in four patients, and five patients had disease confined to the duodenum. Two patients (18.2%) presented with gastric or duodenal involvement. Endoscopic findings were heterogeneous, with diffuse yellowish linear lesions being the most frequently observed in four patients (36.4%). Histopathological analysis revealed AA amyloidosis in three patients, whereas five patients exhibited only amorphous deposits without amyloid A, amyloid P, or light chains. Six patients (54.5%) were asymptomatic at diagnosis, whereas gastrointestinal bleeding was observed in two patients (18.2%). Only one patient (9.1%) experienced disease progression that necessitated systemic chemotherapy. The mean follow-up duration was 20 months, and the 3-year mortality rate was 9.1%. Conclusions: Isolated UGI amyloidosis is a heterogeneous condition that can be easily misdiagnosed. Familiarity with the characteristic endoscopic features and natural disease course is essential for appropriate management.
- 10 December 2025
- Published by Korean College of Helicobacter and Upper Gastrointestinal Research in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
- Vol. 25 (4) , 363-370
Open AccessEndoscopic Diagnosis and Clinical Course of Isolated Upper Gastrointestinal Amyloidosis: A Retrospective Observational Study
Objectives: Early diagnosis of upper gastrointestinal (UGI) amyloidosis and the establishment of appropriate treatment and follow-up strategies remains challenging. This study aimed to elucidate the endoscopic characteristics and clinical courses of patients with isolated UGI amyloidosis. Methods: We retrospectively reviewed 11 patients diagnosed with isolated UGI amyloidosis at Chonnam National University Hospital and Chonnam National University Hwasun Hospital. None of the patients exhibited systemic involvement or multiple myeloma. Clinical data, including endoscopic features, presenting symptoms, and outcomes such as disease progression and mortality, were analyzed. Results: The cohort included seven males (63.6%) and four females (36.4%), with a median age of 72 (37–82) years. Isolated gastric amyloidosis was identified in four patients, and five patients had disease confined to the duodenum. Two patients (18.2%) presented with gastric or duodenal involvement. Endoscopic findings were heterogeneous, with diffuse yellowish linear lesions being the most frequently observed in four patients (36.4%). Histopathological analysis revealed AA amyloidosis in three patients, whereas five patients exhibited only amorphous deposits without amyloid A, amyloid P, or light chains. Six patients (54.5%) were asymptomatic at diagnosis, whereas gastrointestinal bleeding was observed in two patients (18.2%). Only one patient (9.1%) experienced disease progression that necessitated systemic chemotherapy. The mean follow-up duration was 20 months, and the 3-year mortality rate was 9.1%. Conclusions: Isolated UGI amyloidosis is a heterogeneous condition that can be easily misdiagnosed. Familiarity with the characteristic endoscopic features and natural disease course is essential for appropriate management.
- Open Access
- 31 October 2024
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 29 (4) , 144-156
Quality Indicators of Endoscopic Retrograde Cholangiopancreatography in Korea
Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure that requires abundant clinical experience and endoscopic skills, and can lead to various complications, some of which may progress to life-threatening conditions. With expanding indications and technological advancements, ERCP is widely utilized, enhancing procedural accessibility. However, without proper quality management, the procedure can pose significant risks. Quality management in ERCP is essential to ensure safe and successful procedures and meet societal demands for improved healthcare competitiveness. To address these concerns, the Korean Pancreatobiliary Association has developed a Korean-specific ERCP quality indicator reflecting domestic medical environments and realities. Initially, based on a review of foreign ERCP quality indicators and related literatures, key questions were formulated for five preprocedural items, three intra-procedural items, and four post-procedural items. Descriptions and recommendations for each item were selected through peer evaluation. The developed Korean-specific ERCP quality indicator was reviewed by external experts based on the latest evidence and consensus in this fields. This Korean-specific indicator is expected to significantly contribute to improving ERCP quality in Korea, as it is tailored to local needs.
- 31 October 2024
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 29 (4) , 144-156
Open AccessQuality Indicators of Endoscopic Retrograde Cholangiopancreatography in Korea
Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure that requires abundant clinical experience and endoscopic skills, and can lead to various complications, some of which may progress to life-threatening conditions. With expanding indications and technological advancements, ERCP is widely utilized, enhancing procedural accessibility. However, without proper quality management, the procedure can pose significant risks. Quality management in ERCP is essential to ensure safe and successful procedures and meet societal demands for improved healthcare competitiveness. To address these concerns, the Korean Pancreatobiliary Association has developed a Korean-specific ERCP quality indicator reflecting domestic medical environments and realities. Initially, based on a review of foreign ERCP quality indicators and related literatures, key questions were formulated for five preprocedural items, three intra-procedural items, and four post-procedural items. Descriptions and recommendations for each item were selected through peer evaluation. The developed Korean-specific ERCP quality indicator was reviewed by external experts based on the latest evidence and consensus in this fields. This Korean-specific indicator is expected to significantly contribute to improving ERCP quality in Korea, as it is tailored to local needs.
- Open Access
- 31 July 2024
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 29 (3) , 100-104
Mass Forming Autoimmune Pancreatitis, Misdiagnosed as Pancreatic Cancer: Case Report
Autoimmune pancreatitis is characterized by infiltration of the pancreas parenchyma by immunoglobulin G4 (IgG4)-positive plasma cells, chronic inflammation, and fibrosis. It can affect the entire body depending on the subtype. Distinguishing mass-forming type autoimmune pancreatitis from pancreatic cancer can often be challenging. A 60-year-old male presented to our outpatient clinic with abdominal discomfort. Computed tomography revealed a 4.8 cm mass in the pancreatic head obstructing the common bile duct. Endoscopic ultrasound-guided fine needle biopsy and endoscopic retrograde cholangiopancreatography with biliary drainage were performed. Pathological examination revealed no malignant cells, but more than 20 IgG4-positive cells were observed. Following two weeks of steroid treatment, the patient’s symptoms improved, and follow-up imaging showed a reduction in the size of the pancreatic head mass. Herein, we report a case of mass-forming autoimmune pancreatitis initially misdiagnosed as pancreatic cancer.
- 31 July 2024
- Published by Korean Pancreatobiliary Association in The Korean Journal of Pancreas and Biliary Tract
- Vol. 29 (3) , 100-104
Open AccessMass Forming Autoimmune Pancreatitis, Misdiagnosed as Pancreatic Cancer: Case Report
Autoimmune pancreatitis is characterized by infiltration of the pancreas parenchyma by immunoglobulin G4 (IgG4)-positive plasma cells, chronic inflammation, and fibrosis. It can affect the entire body depending on the subtype. Distinguishing mass-forming type autoimmune pancreatitis from pancreatic cancer can often be challenging. A 60-year-old male presented to our outpatient clinic with abdominal discomfort. Computed tomography revealed a 4.8 cm mass in the pancreatic head obstructing the common bile duct. Endoscopic ultrasound-guided fine needle biopsy and endoscopic retrograde cholangiopancreatography with biliary drainage were performed. Pathological examination revealed no malignant cells, but more than 20 IgG4-positive cells were observed. Following two weeks of steroid treatment, the patient’s symptoms improved, and follow-up imaging showed a reduction in the size of the pancreatic head mass. Herein, we report a case of mass-forming autoimmune pancreatitis initially misdiagnosed as pancreatic cancer.
- Open Access
- 11 March 2024
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (4) , 564-577
Quality Indicators of Endoscopic Retrograde Cholangiopancreatography in Korea
Hyung Ku Chon, Ki-Hyun Kim, Tae Jun Song, Dong-Won Ahn, Eaum Seok Lee, Yun Nah Lee, Yoon Suk Lee, Tae Joo Jeon, Chang Hwan Park, Kwang Bum Cho, Dong Wook Lee, Jin-Seok Park, Seung Bae Yoon, Kwang Hyun Chung, Jin Lee, Miyoung Choi. Gut and Liver 2024;18:564-77. https://doi.org/10.5009/gnl230427
- 11 March 2024
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (4) , 564-577
Open AccessQuality Indicators of Endoscopic Retrograde Cholangiopancreatography in Korea
Hyung Ku Chon, Ki-Hyun Kim, Tae Jun Song, Dong-Won Ahn, Eaum Seok Lee, Yun Nah Lee, Yoon Suk Lee, Tae Joo Jeon, Chang Hwan Park, Kwang Bum Cho, Dong Wook Lee, Jin-Seok Park, Seung Bae Yoon, Kwang Hyun Chung, Jin Lee, Miyoung Choi. Gut and Liver 2024;18:564-77. https://doi.org/10.5009/gnl230427
- Open Access
- 20 August 2023
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 11 (2) , 99-103
Management of Malignant Biliary Obstruction Combined with Duodenal Obstruction
Ki-Hyun Kim. Journal of Digestive Cancer Research 2023;11:99-103. https://doi.org/10.52927/jdcr.2023.11.2.99
- 20 August 2023
- Published by Korean Society of Gastrointestinal Cancer Research in Journal of Digestive Cancer Research
- Vol. 11 (2) , 99-103
Open AccessManagement of Malignant Biliary Obstruction Combined with Duodenal Obstruction
Ki-Hyun Kim. Journal of Digestive Cancer Research 2023;11:99-103. https://doi.org/10.52927/jdcr.2023.11.2.99
- Open Access
A Disintegrin and Metalloprotease 12 Promotes Tumor Progression by Inhibiting Apoptosis in Human Colorectal Cancer
A disintegrin and metalloprotease 12 (ADAM12) has been implicated in cell growth, tumor formation, and metastasis. Therefore, we evaluated the role of ADAM12 in colorectal cancer (CRC) progression and prognosis, and elucidated whether targeted downregulation of ADAM12 could lead to therapeutic sensitization. The effect of ADAM12 on tumor cell behavior was assessed in CRC cell lines, CRC tissues, and a mouse xenograft model. ADAM12 overexpression enhanced proliferation, inhibited apoptosis, and acted as positive regulator of cell cycle progression in CRC cells. Phosphorylation of PTEN was decreased and that of Akt was increased by ADAM12 overexpression. These results were reversed upon ADAM12 knockdown. ADAM12 overexpression was significantly associated with the cancer stage, depth of invasion, lymph node metastasis, distant metastasis, and poor survival in CRC patients. In a mouse xenograft model, tumor area, volume, and weight were significantly greater for the ADAM12-pcDNA6-myc-transfected group than for the empty-pcDNA6-myc-transfected group, and significantly lower for the ADAM12-pGFP-C-shLenti-transfected group than for the scrambled pGFP-C-shLenti-transfected group. In conclusion, ADAM12 overexpression is essential for the growth and progression of CRC. Furthermore, ADAM12 knockdown reveals potent anti-tumor activity in a mouse xenograft model. Thus, ADAM12 may serve as a promising biomarker and/or therapeutic target in CRC.
Open AccessA Disintegrin and Metalloprotease 12 Promotes Tumor Progression by Inhibiting Apoptosis in Human Colorectal Cancer
A disintegrin and metalloprotease 12 (ADAM12) has been implicated in cell growth, tumor formation, and metastasis. Therefore, we evaluated the role of ADAM12 in colorectal cancer (CRC) progression and prognosis, and elucidated whether targeted downregulation of ADAM12 could lead to therapeutic sensitization. The effect of ADAM12 on tumor cell behavior was assessed in CRC cell lines, CRC tissues, and a mouse xenograft model. ADAM12 overexpression enhanced proliferation, inhibited apoptosis, and acted as positive regulator of cell cycle progression in CRC cells. Phosphorylation of PTEN was decreased and that of Akt was increased by ADAM12 overexpression. These results were reversed upon ADAM12 knockdown. ADAM12 overexpression was significantly associated with the cancer stage, depth of invasion, lymph node metastasis, distant metastasis, and poor survival in CRC patients. In a mouse xenograft model, tumor area, volume, and weight were significantly greater for the ADAM12-pcDNA6-myc-transfected group than for the empty-pcDNA6-myc-transfected group, and significantly lower for the ADAM12-pGFP-C-shLenti-transfected group than for the scrambled pGFP-C-shLenti-transfected group. In conclusion, ADAM12 overexpression is essential for the growth and progression of CRC. Furthermore, ADAM12 knockdown reveals potent anti-tumor activity in a mouse xenograft model. Thus, ADAM12 may serve as a promising biomarker and/or therapeutic target in CRC.